168 related articles for article (PubMed ID: 30697997)
1. T-Type Channel Druggability at a Crossroads.
Weiss N; Zamponi GW
ACS Chem Neurosci; 2019 Mar; 10(3):1124-1126. PubMed ID: 30697997
[TBL] [Abstract][Full Text] [Related]
2. CRAC channels as targets for drug discovery and development.
Stauderman KA
Cell Calcium; 2018 Sep; 74():147-159. PubMed ID: 30075400
[TBL] [Abstract][Full Text] [Related]
3. T-type calcium channel blockers as neuroprotective agents.
Kopecky BJ; Liang R; Bao J
Pflugers Arch; 2014 Apr; 466(4):757-65. PubMed ID: 24563219
[TBL] [Abstract][Full Text] [Related]
4. T-type calcium channels: From molecule to therapeutic opportunities.
Weiss N; Zamponi GW
Int J Biochem Cell Biol; 2019 Mar; 108():34-39. PubMed ID: 30648620
[TBL] [Abstract][Full Text] [Related]
5. Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases.
Skundric DS
Cent Nerv Syst Agents Med Chem; 2018 Jan; 18(1):3. PubMed ID: 29474167
[No Abstract] [Full Text] [Related]
6. Targeting of CaV3.2 T-type calcium channels in peripheral sensory neurons for the treatment of painful diabetic neuropathy.
Todorovic SM; Jevtovic-Todorovic V
Pflugers Arch; 2014 Apr; 466(4):701-6. PubMed ID: 24482063
[TBL] [Abstract][Full Text] [Related]
7. T-type calcium channels inhibitors: a patent review.
Giordanetto F; Knerr L; Wållberg A
Expert Opin Ther Pat; 2011 Jan; 21(1):85-101. PubMed ID: 21087200
[TBL] [Abstract][Full Text] [Related]
8. Small Molecules as Modulators of Voltage-Gated Calcium Channels in Neurological Disorders: State of the Art and Perspectives.
Lanzetti S; Di Biase V
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209100
[TBL] [Abstract][Full Text] [Related]
9. Discovery and evaluation of Ca
Bezençon O; Remeň L; Richard S; Roch C; Kessler M; Ertel EA; Moon R; Mawet J; Pfeifer T; Capeleto B
Bioorg Med Chem Lett; 2017 Dec; 27(23):5326-5331. PubMed ID: 29074257
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of interleukin-6 on Ca
Liu Q; Chen W; Fan X; Wang J; Fu S; Cui S; Liao F; Cai J; Wang X; Huang Y; Su L; Zhong L; Yi M; Liu F; Wan Y
Exp Neurol; 2019 Jul; 317():226-243. PubMed ID: 30872136
[TBL] [Abstract][Full Text] [Related]
11. Targeting voltage-gated calcium channels in neurological and psychiatric diseases.
Zamponi GW
Nat Rev Drug Discov; 2016 Jan; 15(1):19-34. PubMed ID: 26542451
[TBL] [Abstract][Full Text] [Related]
12. The roles of T-type calcium channel in the development of neuropathic pain following chronic compression of rat dorsal root ganglia.
Wen XJ; Xu SY; Chen ZX; Yang CX; Liang H; Li H
Pharmacology; 2010; 85(5):295-300. PubMed ID: 20453553
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of the Cav3.2 T-type calcium channel directly regulates its gating properties.
Blesneac I; Chemin J; Bidaud I; Huc-Brandt S; Vandermoere F; Lory P
Proc Natl Acad Sci U S A; 2015 Nov; 112(44):13705-10. PubMed ID: 26483470
[TBL] [Abstract][Full Text] [Related]
14. Regulation of T-type calcium channels: signalling pathways and functional implications.
Huc S; Monteil A; Bidaud I; Barbara G; Chemin J; Lory P
Biochim Biophys Acta; 2009 Jun; 1793(6):947-52. PubMed ID: 19071165
[TBL] [Abstract][Full Text] [Related]
15. Discovery and evaluation of Ca
Bezençon O; Remeň L; Richard S; Roch C; Kessler M; Moon R; Mawet J; Ertel EA; Pfeifer T; Capeleto B
Bioorg Med Chem Lett; 2017 Dec; 27(23):5322-5325. PubMed ID: 29066309
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Cav3.2 T-type calcium channel permeability by asparagine-linked glycosylation.
Ondacova K; Karmazinova M; Lazniewska J; Weiss N; Lacinova L
Channels (Austin); 2016; 10(3):175-84. PubMed ID: 26745591
[TBL] [Abstract][Full Text] [Related]
17. Ca
Tracy ME; Tesic V; Stamenic TT; Joksimovic SM; Busquet N; Jevtovic-Todorovic V; Todorovic SM
Neuropharmacology; 2018 Jun; 135():343-354. PubMed ID: 29578032
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain.
Yang HK; Son WS; Lim KS; Kim GH; Lim EJ; Gadhe CG; Lee JY; Jeong KS; Lim SM; Pae AN
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1460-1471. PubMed ID: 30231778
[TBL] [Abstract][Full Text] [Related]
19. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice.
Kraus RL; Li Y; Gregan Y; Gotter AL; Uebele VN; Fox SV; Doran SM; Barrow JC; Yang ZQ; Reger TS; Koblan KS; Renger JJ
J Pharmacol Exp Ther; 2010 Nov; 335(2):409-17. PubMed ID: 20682849
[TBL] [Abstract][Full Text] [Related]
20. CCR2 receptor ligands inhibit Cav3.2 T-type calcium channels.
You H; Altier C; Zamponi GW
Mol Pharmacol; 2010 Feb; 77(2):211-7. PubMed ID: 19864434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
